US 9816092
Modulation of transthyretin expression
granted A61KA61K31/712A61P
Quick answer
US patent 9816092 (Modulation of transthyretin expression) held by Ionis Pharmaceuticals, Inc. expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/712, A61P, A61P1/08, A61P1/10